Cue Biopharma (NASDAQ:CUE – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.
Valuation and Earnings
This table compares Cue Biopharma and Entera Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $27.47 million | 1.85 | -$26.60 million | ($27.02) | -0.26 |
| Entera Bio | $40,000.00 | 13,195.46 | -$11.44 million | ($0.39) | -7.77 |
Entera Bio has lower revenue, but higher earnings than Cue Biopharma. Entera Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cue Biopharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Institutional & Insider Ownership
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 3.7% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Cue Biopharma and Entera Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -435.83% | -620.06% | -291.15% |
| Entera Bio | N/A | -38.55% | -36.15% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cue Biopharma and Entera Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 1 | 0 | 1 | 2.33 |
| Entera Bio | 1 | 0 | 4 | 1 | 2.83 |
Cue Biopharma presently has a consensus price target of $83.00, suggesting a potential upside of 1,087.75%. Entera Bio has a consensus price target of $9.60, suggesting a potential upside of 216.73%. Given Cue Biopharma’s higher possible upside, equities research analysts plainly believe Cue Biopharma is more favorable than Entera Bio.
Summary
Entera Bio beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.
About Entera Bio
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
